TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02511236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy
Description: The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include a functional analysis of smoking patterns, environmental cues, and motivation for change, and cover nicotine addiction and withdrawal, health consequences, benefits of cessation, stress management, negative affect, alcohol use, triggers, coping responses, cognitive restructuring, social support, decision making, weight control, and physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Education
Description: The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include didactic information on tobacco-associated morbidities, such as heart disease, diabetes, and hypertension. Content may include Power Point-delivered lectures on the prevalence, etiology, basic pathology, symptom patterns, and treatment of the conditions, and discussion questions designed to facilitate learning and interest. Smoking cessation specific topics will not be addressed, and coping skills will not be provided. Participants will be allowed to share feelings regarding smoking (if they mention them) and general questions will be answered, although no specific behavioral quitting advice will be provided (i.e., they will be encouraged to adhere to the TNP protocol).
Study: NCT03503370

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the placebo will wash their feet using COMFORT BATH CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
Study: NCT02511236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal Nicotine Patch
Description: Participants will be prescribed up to 8 weeks of transdermal nicotine patch therapy, including 21 mg for 4 weeks, 14 mg for 2 weeks, and 7 mg for 2 weeks. Dosages will be adjusted per manufacturer recommendations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine Patch
Description: Participants will be prescribed up to 8 weeks of transdermal nicotine patch therapy, including 21 mg for 4 weeks, 14 mg for 2 weeks, and 7 mg for 2 weeks. Dosages will be adjusted per manufacturer recommendations.
Study: NCT04615442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epihunter
Description: Subjects wear epihunter during routine video EEG
Study: NCT02123056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
Study: NCT04419532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1055a
Description: Administered as an intravenous infusion on Day 1 of every 21-day cycle following low dose administration(s) in priming dose period.~Infusion duration: 180 minutes for the first infusion, and if no infusion-related reaction, 120 minutes for subsequent infusions
Study: NCT02123056

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
Study: NCT00790244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin , ifosfamide
Description: doxorubicin 60mg/m2+ifosfamide 6g/m2 every third week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin , ifosfamide
Description: doxorubicin 60mg/m2+ifosfamide 6g/m2 every third week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin , ifosfamide
Description: doxorubicin 60mg/m2+ifosfamide 6g/m2 every third week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin , ifosfamide
Description: doxorubicin 60mg/m2+ifosfamide 6g/m2 every third week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin, ifosfamide
Description: Doxorubicin and Ifosfamide given every three weeks, totally 6 courses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin, ifosfamide
Description: \<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and four.~(\>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin, ifosfamide
Description: \<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.~(\>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)
Study: NCT01862250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine (Duraclon®)
Description: Clonidine at dosing intervals of 6, 8, 12, 18 or 24 hours. If the following is observed the event will be recorded, and no additional clonidine will be given and blood will be drawn to measure plasma level of clondine.~* 10 mm Hg reduction in MAP or MAP ≤ 40 mm Hg sustained for ≥30 min after administration~* 20% drop in HR from the infant's baseline, sustained for ≥30 min after administration~* HR ≤70/min, sustained for ≥30 min after administration
Study: NCT01466803

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will be given placebo twice a day for 5 days prior to the study
Study: NCT01148160

Intervention type: DRUG
Intervention: voriconazole
Description: intravenous, oral administration
Study: NCT04542421

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasound use in patients hospitalized with COVID
Description: Hospitalists will be taught to use lung ultrasound in the management of their patients with COVID
Study: NCT02644863

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175mg/m2 IV over 2 hours,day 1; Repeat every 3 weeks;regimen for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175mg/m2 IV over 2 hours,day 1; Repeat every 3 weeks;regimen for 3 cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK
Description: Antigen-sensitized DC-CIK 8×10\^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 30mg/m2 IV on 1-3 days, Repeat every 3 weeks;regimen for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 30mg/m2 IV on 1-3 days, Repeat every 3 weeks;regimen for 3 cycles
Study: NCT02207803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition Assistance Program
Study: NCT03500783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: 40 ppm of exogenous gaseous nitric oxide is supplied directly to the oxygenator in the cardiopulmonary bypass circuit during coronary artery bypass grafting.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard CPB
Description: Standard protocol of delivery of air gas mixture to the cardiopulmonary bypass circuit
Study: NCT03597750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repose®
Description: * Repose® Mattress~* Repose® Cushion~* Repose® Wedge or Foot Protectors
Study: NCT03884699

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Accuracy of planned transverse Maxillary distance using Mimics software after fixation using Patient specific implant
Description: Virtual planning: based on clinical evaluation and 3D cephalometric analysis. Virtual osteotomies mimicking segmental Lefort I and a bilateral sagittal split osteotomy.~Designing the virtual cutting guide. Virtual movement into the desired positions of the segmented maxilla and mandible, based on: clinical evaluation, 3D cephalometric analysis and the desired occlusion.~Once the optimal position of the maxilla is achieved, a patient specific implant will be virtually designed to fix the segmented maxilla in its new position.~Fabrication of the cutting guide using additive manufacturing technique from polymer material.~Fabrication of PSI from titanium alloy using additive manufacturing technique.
Study: NCT04449302

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate molar implant with customized healing abutment
Description: Patients will receive an immediate implant with customized healing abutment~1. Atraumatic extraction without flap elevation using periotomes and elevators then sectioning of the roots will be performed to preserve the interseptal bone.~2. The drilling will be performed starting from the pilot drill in the interseptal bone to the twisting drills according to the manufacturer's instructions to the selected implant size. The implant is to be placed immediately then the insertion torque will be measured using a torque wrench. In order to place the customized healing abutment, the insertion torque should be more than 25 ncm.~3. The gap distance will be filled by xenograft, a plastic abutment will be screwed in place then a flowable composie resin will be applied around into small amounts and cured to take the soft tissue contour then finishing and polishing of the customized healing abutment will be done.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate molar implant with customized healing abutment
Description: Patients will receive an immediate implant with customized healing abutment~1. Atraumatic extraction without flap elevation using periotomes and elevators then sectioning of the roots will be performed to preserve the interseptal bone.~2. The drilling will be performed starting from the pilot drill in the interseptal bone to the twisting drills according to the manufacturer's instructions to the selected implant size. The implant is to be placed immediately then the insertion torque will be measured using a torque wrench. In order to place the customized healing abutment, the insertion torque should be more than 25 ncm.~3. The gap distance will be filled by xenograft, a plastic abutment will be screwed in place then a flowable composie resin will be applied around into small amounts and cured to take the soft tissue contour then finishing and polishing of the customized healing abutment will be done.
Study: NCT03109353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECP with 5-aminolevulinic acid
Description: extracorporeal photopheresis (ALA-ECP) using 5-aminolevulinic acid instead of psoralen (8-MOP) in a maximum of 10 treatment cycles
Study: NCT00931437

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin K-rich dairy product
Description: several forms of vitamin K: phylloquinone, menaquinone-7,-8,-9,and -10.
Study: NCT01103258

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high ligation and stripping (surgery)
Description: surgery consisting of high ligation in combination with long saphenous stripping

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FOAM
Description: duplex guided foam sclerotherapy
Study: NCT03620123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab
Description: Nivolumab 3 mg/kg of body weight intravenous infusion every two weeks and ipilimumab 1 mg/kg of body weight intravenous infusion every six weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: docetaxel 75 mg/m² intravenous infusion every three weeks
Study: NCT01475851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK548470 300 mg tablet
Description: Blue tablets containing 300 mg of tenofovir disoproxil fumarate
Study: NCT00392743

Intervention type: PROCEDURE
Intervention: pet/spect scan
Study: NCT04290416

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microwire electrodes
Study: NCT01024036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Siltuximab 11 mg/kg will be administered by 1-hour intravenous infusion every 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by 1-hour intravenous infusion every 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care (BSC)
Description: BSC included treatment for effusions, antipyretics, antipuretics, antihistamines, pain medication, treatment for infections, transfusions, management of infusion-related reactions, and corticosteroids.
Study: NCT05405946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Remediation Therapy
Description: Sessions of 45 minutes will be developed 2 times a week, for 4-5 months (performing a total of 40 sessions). The sessions will be led by an experienced clinician with psychotic patients, and trained for the management of CCRT. Each intervention session will be individualized according to the results of the evaluation tests and the computerized program itself will adapt the difficulty of the tasks according to the performance of each patient.~The cognitive remediation NeuroPersonalTrainer platform includes two rehabilitation modules: the cognition module that includes attention, memory and executive functions with different levels of complexity and the Social Cognition module which allows working on different aspects of emotional processing, theory of mind and cognitive biases through 43 tasks based on multiple multimedia materials.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Patients receiving TAU include psychoeducation about the disorder, psychiatric visits, and follow-up and review of drug treatment. In addition, they make individual visits with psychology, nursing and / or social work. In all cases, patients are treated in outpatient clinics.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Patients receiving TAU include psychoeducation about the disorder, psychiatric visits, and follow-up and review of drug treatment. In addition, they make individual visits with psychology, nursing and / or social work. In all cases, patients are treated in outpatient clinics.
Study: NCT01322490

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-F

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-F

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GM-CSF Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: GM-CSF Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PROSTVAC V/F Placebo
Study: NCT04768101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]-PIB
Description: \[11C\]-PIB is a PET radiotracer used to evaluate levels of Αβ burden.
Study: NCT01661101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Dabigatran 110 mg taken twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Dabigatran)
Description: Dabigatran placebo taken twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole 20 mg capsule taken once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Omeprazole)
Description: Omeprazole placebo taken once daily
Study: NCT01069510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 25mg
Description: Spironolactone 25 mg daily for 12 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for 12 months
Study: NCT04042688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraarticular administration of tranexamic acid
Description: Intraarticular administration with concentration of 30mg/mL was selected. The operation room nurses prepared 3g tranexamic acid in 100 mL of saline solution during operation. After finishing surgical wound suture and orthopaedic surgeons related to this study left operation room, the orthopaedic residents who were not involved in the postoperative evaluation administered tranexamic acid solution through suprapatellar pouch before tourniquet release in patients in the treatment group. The control group did not receive any solution. intraarticular drain was not inserted in all patients.
Study: NCT04404517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Monoclonal antibody used in IBD treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Monoclonal antibody used in IBD treatment
Study: NCT04214561

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: Each of the patients will undergo polysomnography

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: Each of the patients will undergo polysomnography
Study: NCT02683928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBR 830

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02953210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexter ketamine
Description: multimodal anesthesia without opioids ketamine as induction drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: continuous infusion intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Hydrochloride
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine Hydrochloride
Description: clonidine intravenous pre induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Hydrochloride
Description: premedication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Hydrochloride
Description: premedication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane Volatile Liquid
Description: maintenance of general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane Volatile Liquid
Description: maintenance of general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium Injectable Solution
Description: induction of general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium Injectable Solution
Description: induction of general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 1 % Injectable Suspension
Description: induction of general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol 1 % Injectable Suspension
Description: induction of general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone-21-Sulfobenzoate, Sodium Salt
Description: at the end of the procedure 4mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone-21-Sulfobenzoate, Sodium Salt
Description: at the end of the procedure 4mg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine Hydrochloride
Description: at the end of the procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine Hydrochloride
Description: at the end of the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron Hydrochloride
Description: at the end of the procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Hydrochloride
Description: at the end of the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Injectable Solution
Description: at the of the procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Injectable Solution
Description: at the of the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: at the end of the procedure for infiltration of trocar wounds

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: at the end of the procedure for infiltration of trocar wounds
Study: NCT04322604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lirentelimab (AK002)
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01040702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: a single doses of 10-20 mg in each one of two visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: a single doses of 10-20 mg in each one of two visits

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sweetener pill
Description: a capsule containing a sweetener pill

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sweetener pill
Description: a capsule containing a sweetener pill
Study: NCT03092284

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)
Description: Direct intramyocardial injection of CSCC_ASC

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT00850889

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid gel (24 mg/mL) with 0.3% lidocaine
Description: Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A gel of hyaluronic acid (concentration of 20 mg/mL)
Description: Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL
Study: NCT01024036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: BSC included treatment for effusions, antipyretics, antipuretics, antihistamines, pain medication, treatment for infections, transfusions, management of infusion-related reactions, and corticosteroids.
Study: NCT04572178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash payment and brief behavioral counseling
Description: The intervention consists of: (i) in person brief behavioral counseling, (ii) the evaluation of the smoking status using breath carbon monoxide, and (iii) cash payment of 25 Euro if the reading does not exceed a carbon monoxide value 3 ppm ( ppm = parts per million) on two consecutive measurements per week. The intervention starts at the earliest in pregnancy week 15 and lasts until the delivery. If they relapse, the reward is not paid. However, in the following week they have the opportunity to quit smoking and being rewarded again.